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Abstract
OXPHOS is believed to play an important role in non-alcoholic fatty liver disease (NAFLD),
however, precise mechanisms whereby OXPHOS influences lipid homeostasis are incom-
pletely understood. We previously reported that ectopic expression of LRPPRC, a protein
that increases cristae density and OXPHOS, promoted fatty acid oxidation in cultured pri-
mary hepatocytes. To determine the biological significance of that observation and define
underlying mechanisms, we have ectopically expressed LRPPRC in mouse liver in the set-
ting of NAFLD. Interestingly, ectopic expression of LRPPRC in mouse liver completely inter-
dicted NAFLD, including inflammation. Consistent with mitigation of NAFLD, two markers of
hepatic insulin resistance—ROS and PKCε activity—were both modestly reduced. As re-
ported by others, improvement of NAFLD was associated with improved whole-body insulin
sensitivity. Regarding hepatic lipid homeostasis, the ratio of NAD+ to NADH was dramatical-
ly increased in mouse liver replete with LRPPRC. Pharmacological activators and inhibitors
of the cellular respiration respectively increased and decreased the [NAD+]/[NADH] ratio, in-
dicating respiration-mediated control of the [NAD+]/[NADH] ratio. Supporting a prominent
role for NAD+, increasing the concentration of NAD+ stimulated complete oxidation of fatty
acids. Importantly, NAD+ rescued impaired fatty acid oxidation in hepatocytes deficient for
either OXPHOS or SIRT3. These data are consistent with a model whereby augmented he-
patic OXPHOS increases NAD+, which in turn promotes complete oxidation of fatty acids
and protects against NAFLD.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming one of the leading causes of
liver disease in Western societies [1]. NAFLD spans a spectrum of disease. In simple steatosis,
there is benign accumulation of hepatic lipid [2]. In steatohepatitis, inflammation and
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attendant hepatocyte injury occur, which together may progress to fibrosis or, on rare occasion,
hepatocellular carcinoma [3,4]. Worldwide, the prevalence of fatty liver disease is 10–30%
[5,6]. Obesity and diabetes constitute key factors in its development. Recent work has demon-
strated that, in NAFLD, hepatic insulin resistance exacerbates whole body insulin resistance
[7]. Efforts to mitigate NAFLD are, thus, anticipated to improve not only fatty liver disease but
also mitigate whole body insulin resistance and diabetes. Central to this goal is deciphering the
key pathways that influence non-alcoholic fatty liver.
Defective mitochondrial oxidative phosphorylation (OXPHOS) features prominently in
NAFLD. There is a striking negative association between OXPHOS and NAFLD. Notably,
OXPHOS activity is decreased in patients with non-alcoholic fatty liver disease [8,9]. Function-
al changes are supported by energetically unfavorable perturbations in mitochondrial cristae,
which are the structural underpinning of OXPHOS [10,11]. These changes are accompanied
by both activation of protein kinase C epsilon (PKCε) via increased diacylglycerol (DAG) and
an increase in mitochondrial reactive oxygen species (ROS) [12,13]. Both pathways have been
implicated in hepatic insulin resistance, and thus, proposed as important mediators of hepatic
insulin resistance in NAFLD. Additionally, fatty liver associates with reductions in OXPHOS-
dependent [NAD+]/[NADH], which allosterically regulates complete oxidation of fatty acids
via the citric acid cycle [14,15]. Due to a number of confounding variables, a causal role for de-
fective OXPHOS in NAFLD and putative underlying mechanisms remains obscure. Hitherto,
efforts to increase OXPHOS in liver have been thwarted by a lack of genetic (or pharmacologi-
cal) tools that specifically augment hepatic OXPHOS in vivo. Hence, the precise role of aug-
mented OXPHOS in NAFLD remains an open question.
Here we activate OXPHOS in liver and show that it interdicts NAFLD and mitigates whole
body insulin resistance. We increased OXPHOS in mouse liver by ectopically expressing leu-
cine-rich pentatricopeptide repeat containing (LRPPRC; but also called LRP130). LRPPRC is a
130 kD protein that is defective in Leigh Syndrome French Canadian variant, a rare form of the
mitochondrial disorder Leigh Syndrome [16]. In both gain- and loss-of-function models,
LRPRPC regulates mitochondrially encoded gene expression, which in turn regulates the ex-
pression of 13 polypeptides central to the formation of mature OXPHOS complexes [17–23].
LRPPRC is reported to regulate mitochondrially encoded gene expression by increasing mito-
chondrial transcription [18–20] as well as stabilizing some mitochondrially encoded transcripts
[22,24]. Because an increase in mitochondrially encoded subunits is sufficient to drive mature
OXPHOS complexes, ectopic expression of LRPPRC increases mitochondrial OXPHOS and
oxygen consumption [18,19]. Using mice with transgenic expression of LRPPRC in liver, we
show enhanced hepatic OXPHOS protects against fatty liver and reduces liver inflammation in
the setting of diet-induced obesity. Additionally, hepatic and whole-body insulin sensitivity
were increased, changes possibly explained by reduced reactive oxygen species and diminished
PKCε activation. Mice with enhanced hepatic OXPHOS have a dramatic increase in the ratio
of [NAD+]/[NADH], which promotes complete lipid oxidation in hepatocytes. Using pharma-
cological activators and inhibitors of cellular respiration, we demonstrate that respiratory ca-
pacity dictates [NAD+]/[NADH] in hepatocytes. Moreover, increasing the concentration of
NAD+ in hepatocytes promotes complete fatty acid oxidation, and rescues impaired fatty acid
oxidation in hepatocytes deficient for either OXPHOS or SIRTUIN 3 (SIRT3). Taken together,
these data suggest that augmented hepatic OXPHOS enhances NAD+, which in turn promotes
complete fatty acid oxidation and interdicts NAFLD.
Augmented OXPHOS Interdicts NAFLD
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Materials and Methods
Animal Model
Liver-specific Lrpprc transgenic mice were created as described previously [18]. Liver-specific
expression was driven by a transthyretin enhancer and promoter. These mice were backcrossed
to a C57BL/6 background for at least 6 generations. Wild-type littermate control mice were
used to make comparisons. Mice were housed in a facility with 12h light/12h dark cycle. For
high-fat diet feeding, male mice aged 7 weeks were fed a 55% kcal from fat diet (Harlan Teklad
TD-93075) for 12 weeks before metabolic phenotyping. Following the designated high-fat feed-
ing period, mice were sacrificed by CO2 euthanasia and tissues embedded for histology or
flash-frozen in liquid nitrogen for further analysis. All animal experiments were approved by
the IACUC of the University of Massachusetts Medical School (Protocol #A-2085-12).
Pathological Assessment of Liver
Hepatic steatosis and inflammation in liver sections was assessed by an unbiased pathologist as
previously described [25]. Briefly, steatosis was graded as Healthy (<5% of liver involvement),
Mild (5–33%), Moderate (34–66%) or Severe (>66%), and inflammation as Healthy (no in-
flammation), Mild (1–2 foci per 10X field), Moderate (2–4 foci), or Severe (>4 foci).
Metabolic Cage Analysis
Analysis of energy expenditure, activity, and food intake was performed by the University of
Massachusetts Mouse Metabolic Phenotyping Core using metabolic cages (TSE Systems).
Protein and Gene Expression
Whole tissue lysates were harvested by homogenization in a TissueLyzer (Qiagen) using lysis
buffer (50mM Tris pH 7.5, 0.15mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1mM
EDTA) including a protease inhibitor cocktail (Sigma) and separated by SDS-PAGE (Invitro-
gen). Samples were transferred to a PVDF membrane and blocked in 5% BSA solution for 1
hour, then incubated with primary antibody overnight at 4°C. Membranes were washed three
times with tris-buffered saline (50mM Tris, 150mMNaCl, 0.1% Tween-20, pH 7.6) then
probed with the appropriate secondary antibody for 1 hour at room temperature. Following
secondary incubation, samples were washed as above and proteins detected using ECL (GE
Healthcare). Antibodies to LRPPRC were generated as previously described [18]. Antibodies
for Myc, Actin (Santa Cruz), COX1, Citrate Synthase, VDAC (MitoSciences), phospho-AKT,
AKT (Cell Signaling) were purchased and diluted according to the manufacturer instructions.
Densitometric analysis was performed using ImageStudio (Licor) by comparison to a reference
protein (actin). RNA samples were harvested from tissue in Trizol (Invitrogen) and analyzed
as described previously [18].
Mitochondrial Respiration, Complex Activity, and Isolation of Primary
Hepatocytes
Mitochondria were harvested from chow-fed WT and Tg/Tg mouse livers and oxygen con-
sumption in the presence of pyruvate and malate measured on a Clarke-type electrode (Hansa-
tech) as previously described [26] using 0.5 mg of mitochondrial protein. All mitochondria
used had an RCR> 3.0 and membrane integrity> 80%. Individual respiratory complex activi-
ty was performed as previously described [18]. Primary hepatocytes fromWT and Lrpprc
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transgenic mice were isolated by perfusion and collagenase treatment as previously described
[27].
Measurement of Liver and Serum Triglycerides
Triglyceride levels in serum and liver from mice fasted for 16 hours were measured by PicoP-
robe fluorometric assay (BioVision) according to the manufacturer’s specifications. For liver,
~10 mg of tissue was homogenized in 5% Triton X-100 in water using a TissueLyzer (Qiagen)
then boiled twice for 5 minutes to solubilize lipids. Samples were spun 13,000 x g for 5 minutes
to pellet insoluble materials, then assayed using the provided materials. Values were normal-
ized to protein concentration as measured by BCA assay (Thermo).
Glucose and Insulin Tolerance Testing
Glucose tolerance testing was performed after an overnight fast by intraperitoneal injection
of 1.5 mg/g dextrose. Blood glucose content was analyzed at 15, 30, 60, 90, and 120 minutes by
tail vein sampling. For insulin tolerance, mice were fasted 6 hours, then injected with
0.75mU/g human insulin and monitored similarly. Blood glucose levels were determined using
a OneTouch Ultra monitor and strips (LifeScan).
Determination of Mitochondrial Superoxide, Proton Gradient, and PKCε
Acvitiy
We used MitoSox Red (Invitrogen) per manufacturer protocol to measure mitochondrial su-
peroxide in human hepatoma (HepG2) cells stably expressing ectopic human Lrpprc. Proton
gradient was determined in cells plated in a 96-well dish by staining with 1μg/mL JC-1 dye
(Life Technologies) for 20 minutes at 37°C per manufacturer instructions.
Cytosolic and membrane-bound PKCε was determined by fractionation and immunblotting
as previously described [28]. The presence of PKCε was determined by immunoblot and activity
calculated using the ratio of membrane to cytosolic signal as determined by densitometry.
Nicotinamide Treatment and [NAD+]/[NADH] Measurement
Primary hepatocytes were incubated for 16 hours in serum-free medium in the presence or ab-
sence of nicotinamide (NAM) at the doses indicated. For inhibitor experiments, cells were incubat-
ed for 2 hours in the presence of 4 μMCarbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
(FCCP) or 1 μM rotenone. Measurement of NAD+ and NADHwas performed using the EnzyFluo
[NAD+]/[NADH] kit (BioAssays) per the manufacturer’s instructions.
Fatty Acid Oxidation Assay
The oxidation of palmitate was measured in primary hepatocytes as previously described with
minor modifications [18]. Briefly, primary hepatocytes were incubated in serum-free medium
containing 20nM glucagon ± NAM for 16 hours. Following this incubation, medium was
changed to DMEM with 1% BSA Fraction V, 20 mMHEPES, and 250 μM cold palmitate. Fol-
lowing incubation at 37°C for 2 hours, wells were spiked 14C-palmitic acid and incubated for
an additional 90 minutes. Complete oxidation of palmitate was measured by the release of 14C-
carbon dioxide after addition of perchloric acid (10% v/v final concentration). Chemical inhibi-
tion of OXPHOS was accomplished by treatment with either 4 μM FCCP or 1 μM rotenone
30 minutes prior to the addition of radiolabeled substrate.
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Statistics
Statistical analyses were performed using GraphPad (Prism) or SAS/STAT. Differences in pro-
tein densitometry, cellular respiration, relative mtDNA levels, area-under-the-curve for glucose
and insulin tolerance tests, triglyceride levels, and mitochondrial membrane potential were com-
pared by two-tailed, unpaired Student’s t-test. Membrane-bound and membrane-to-cytosol ra-
tios of PKCε were compared using a one-tailed, unpaired Student’s t-test. Gene expression was
analyzed by either two-tailed, unpaired Student’s t-test (nuclear encoded transcription factors)
or by two-way ANOVA using Bonferroni’s post test. Comparison of maximal respiration to
LRPPRC protein levels was performed using linear regression. Steatosis and inflammation grad-
ing was assessed by chi-square analysis. For determination of differences in mouse weight
curves, a mixed model with Bonferroni correction was performed. In general, P values less than
0.05 were considered significant.
Results
Ectopic expression of liver-specific LRPPRC promotes hepatic
OXPHOS
In order to assess the role of OXPHOS in the progression of NAFLD in vivo, we ectopically ex-
pressed Lrpprc (also called Lrp130) in a liver-specific manner. As shown in Fig 1A and 1B,
there is a dose-dependent increase of LRPPRC protein in liver harvested from hemizygous
(Tg/0) and double-hemizygous transgenic mice (Tg/Tg). Gene expression for Lrpprcmatched
LRPPRC protein levels (Fig 1E and S1 Fig). Importantly, ectopic expression of LRPPRC protein
was not observed in other tissues, supporting liver-specific expression (Fig 1C). Because double
transgenic mice had the greatest expression of LRPPRC protein, and we sought to maximize
our model of hepatic OXPHOS, double hemizygous mice became the major focus of our stud-
ies, while hemizygous mice were used in select experiments. Throughout our studies, the phe-
notype of hemizygous mice was intermediate between wild-type littermate control mice and
double hemizygous transgenic mice. Consistent with prior reports, ectopically expressed
LRPPRC resulted in increased mitochondrially encoded gene expression (Fig 1F and S1 Fig).
Additionally, protein analysis in primary hepatocytes isolated from Tg/Tg mice showed greater
COX1 protein levels compared with WTmice (Fig 1D). We did not observe changes in several
markers of mitochondrial content—mRNA expression of Polrmt, Tfam, and Tfb2m (Fig 1E),
protein expression of citrate synthase or VDAC (Fig 1A), or mtDNA copy number (Fig 1G),
suggesting augmentation of OXPHOS was not due to increased mitochondrial mass.
Next, we tested if ectopic expression of hepatic LRPPRC could augment OXPHOS in mouse
liver mitochondria. Using mitochondria isolated from livers of chow fed wild-type littermate
control mice and Tg/Tg mice, we measured oxygen consumption using a Clarke-type electrode
(Fig 2A). While basal (state II and IV) respiration was unchanged in transgenic mitochondria,
ADP-stimulated respiration (state III) was increased (Fig 2B and 2C). Furthermore, the level of
LRPPRC protein predicted maximal oxygen consumption (FCCP) in both WT and Tg/Tg mi-
tochondria (r2 = 0.948, p = 0.001), indicating that respiratory capacity directly correlates with
LRPPRC protein expression (Fig 2D). Compared with WT mitochondria, Tg/Tg mitochondria
had equivalent levels of proton leak (data not shown), indicating that the increase in oxygen
consumption was attributable to bona fideOXPHOS. These functional measurements are in
agreement with observed increases in complex I, III, IV and V activities for cells replete with
LRPPRC (S2 Fig and ref. [18]).
Increased oxygen consumption could result from enhanced efficiency of OXPHOS or an in-
crease in the number of OXPHOS units per mitochondrion, that is, cristae density. As shown
Augmented OXPHOS Interdicts NAFLD
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in Fig 2E, the P:O ratio (that is, the ratio of ATP molecules generated per molecule of oxygen
consumed in state III) was unaltered in transgenic mitochondria, indicating increased
OXPHOS units per mitochondrion. While we did not measure cristae density in this study,
these data are consistent with previous reports by our group and others demonstrating a role
for LRPPRC in regulating mitochondrial cristae density [18,21]. In summary, ectopic expres-
sion of LRPPRC in the liver augments hepatic OXPHOS without gross alterations in mitochon-
drial mass.
Augmented hepatic OXPHOS improves whole body insulin sensitivity
The liver plays an important role in regulating whole body metabolic homeostasis. Therefore,
we characterized the effect of enhanced hepatic OXPHOS on whole-body energy balance and
insulin sensitivity. On a chow diet, WT,Tg/0, and Tg/Tg mice had no significant differences in
weight or whole body insulin sensitivity as assessed by ITT or GTT (data not shown). In order
to determine the role of increased hepatic OXPHOS in NAFLD, we induced fatty liver by feed-
ing mice a high-fat diet (HFD; 55% kcal fat) for 12 weeks. Expression of Lrpprc and mito-
chondrially encoded OXPHOS genes remained elevated in Tg/Tg mice following high-fat
feeding (S3 Fig). As shown in Fig 3A and 3B, mice with augmented hepatic OXPHOS had im-
proved insulin sensitivity as assessed by ITT and GTT. Improvement in insulin sensitivity was
dependent on the dose of LRPPRC, since double transgenic were more insulin sensitive than
Fig 1. LRPPRC promotes mitochondrially encoded gene expression in liver. (A) Protein expression and (B) quantification in livers of wild-type littermate
controls (WT), hemizygous (Tg/0), and double hemizygous (Tg/Tg) LRPPRC transgenic mice. (C) Protein expression in heart, spleen, brown adipose tissue
(BAT) and liver in WT and Tg/Tg mice. (D) Protein expression in WT and Tg/Tg cultured primary hepatocytes. (E) Nuclear Lrpprc, mitochondrial polymerase
(Polrmt), mitochondrial transcription factor A (Tfam), and mitochondrial transcription factor B2 (Tfb2m) and (F) mitochondrially encoded respiratory complex
subunit gene expression in Tg/Tg and control livers. (G) Genetic determination of mitochondrially encoded DNA content in the samples. For all experiments,
n = 3 or 4. Data are mean ± SEM * p<0.05, ** p<0.01, *** p<0.001 vs. WT by two-tailed unpaired Student’s t-test (B, E, G) or 2-way ANOVA with
Bonferroni’s post-test (F).
doi:10.1371/journal.pone.0125617.g001
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single transgenic liver-specific LRPPRC mice. Alterations in insulin sensitivity can be due to a
multitude of factors, thus we evaluated processes that might explain this finding. Though
weight gain was similar between all groups throughout most of the feeding timeline, there was
a modest reduction in weight in Tg/Tg mice following 12-weeks of HFD (Fig 3C). Even so,
there was a strong trend toward insulin sensitivity prior to changes in weight (data not shown),
implying intrinsic effects independent of weight loss. To further evaluate this discrepancy in
weight, we performed metabolic cage analysis of WT and Tg/Tg mice fed a HFD. Though
there was no difference in daily activity or food intake (Fig 3D and 3E), mice with augmented
hepatic OXPHOS tended to have increased diurnal energy expenditure (Fig 3F). We, therefore,
screened several factors involved in whole body energy balance—hepatic Fgf21, hepatic Il6, and
skeletal muscle Irisin; however, none of the mRNAs for these factors were altered (data not
shown).
Since transgenic Lrpprc expression in our model is restricted to the liver (Fig 1C), we evalu-
ated potential mechanisms by which augmented OXPHOS confers insulin sensitivity.
Fig 2. Liver-specific LRPPRC augments hepatic OXPHOS. (A) Representative plot, (B) absolute and (C) relative changes in oxygen consumption rate
(OCR) in isolated mitochondria fromWT and LRPPRC Tg/Tg livers measured on a Clarke-type electrode. (D) FCCP induced maximal OCR vs. LRPPRC
protein levels in isolated mitochondria fromWT and Tg/Tg livers. (E) P:O ratio calculated from Clarke-electrode data. For all experiments, n = 3 or 4. Data are
mean ± SEM (B—E), * p<0.05, ** p<0.01, *** p<0.001 by two-tailed unpaired Student’s t-test (B, C) or linear regression (D).
doi:10.1371/journal.pone.0125617.g002
Augmented OXPHOS Interdicts NAFLD
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Fig 3. Hepatic OXPHOS enhances whole body insulin sensitivity. (A) Glucose and (B) insulin tolerance tests and area-under-the-curve (insets) and (C)
weights in wild-type littermate control mice (WT), LRPPRC single hemizygous (Tg/0), and double hemizygous (Tg/Tg) mice fed a high-fat diet for 12 weeks,
n = 10. (D) Hourly activity, (E) daily food intake, and (F) diurnal energy expenditure (7AM—7PM) in WT and Tg/Tg mice fed a high-fat diet > 20 weeks n = 3–6.
Augmented OXPHOS Interdicts NAFLD
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Specifically we focused on ER stress, reactive oxygen species (ROS), and protein kinase C epsi-
lon (PKCε) activation. As shown in Fig 3G, we saw no change in several mRNA known to cor-
relate with ER stress. Regarding ROS, Ucp2 and iNOS, which are markers of oxidative stress,
were reduced in high-fat fed Tg/Tg livers (Fig 3H). Consistent with these results, ectopic Lrpprc
expression in human hepatoma cells (HepG2 cell line) reduced mitochondrial superoxide pro-
duction as assessed by MitoSox Red (Fig 3I). This indicates LRPPRC is sufficient to reduce
ROS formation in a cell autonomous fashion. Mitochondrial production of ROS is, in part, de-
pendent on inner membrane proton gradient [29]. Cells ectopically expressing LRPPRC had
lower proton gradients compared with controls (Fig 3J), suggesting a likely mechanism for re-
duced mitochondrial superoxide. Because coupled respiration is increased (Fig 2), a reduced
proton gradient could suggest enhanced proton pumping coupled with a disproportionately
greater activity at complex V, which dissipates the proton gradient. This is consistent with pre-
vious work indicating differential effects of LRPPRC on Complex V [18,30].
To exclude weight reduction as a potential confounding factor in insulin resistance, we next
evaluated insulin induced phosphorylation of AKT (pAKT) in primary hepatocytes isolated
from mice on a chow fed diet. As shown in Fig 3K, primary hepatocytes from mice with aug-
mented hepatic OXPHOS had modestly increased pAkt in response to insulin treatment.
These data suggest two key findings. One, augmented hepatic OXPHOS modestly improves he-
patocyte insulin signaling in a cell autonomous manner and lowers the mitochondrial proton
gradient culminating in lower ROS. Two, improved hepatocyte signaling promotes whole body
insulin signaling only in the setting of metabolic stress.
In fatty liver disease, increased triglyceride content promotes the accumulation of diacylgly-
cerol (DAG) species, which in turn activates PKCε. Upon activation, PKCε translocates from
the cytosol to the membrane, where it phosphorylates insulin receptor beta, culminating in im-
paired insulin signaling [31,32]. Assessment of membrane bound PKCε is, thus, a readout of
PKCε activation and correlates with insulin resistance [33]. Activation of PKCε was reduced in
mice with augmented hepatic OXPHOS (Fig 3L—3N). These data could imply decreased total
lipid burden in liver with augmented OXPHOS.
Augmented hepatic OXPHOS protects against NAFLD
We hypothesized that enhanced OXPHOS might influence the course of NAFLD. We tested
this hypothesis by feeding mice a HFD for 12 weeks to induce fatty liver disease. In mice, diet-
induced NAFLD only results in modest inflammation. Nonetheless, this modest inflammation
was reduced in transgenic mice compared with littermate control mice (Fig 4A and 4B,
p = 0.16, chi-squared). In Tg/Tg mice, the frequency of mice with healthy livers was increased
(30% Tg/Tg vs. 0% control). Similarly, the frequency of mice with moderate hepatic inflamma-
tion was reduced 2.2-fold (20% Tg/Tg mice vs. 44% control). In support of histological
grading, the expression of panel of inflammatory genes was reduced in mouse liver from Tg/Tg
mice (Fig 4C). Notably, Ccl2 (also calledMcp1), a monocyte chemoattractant, was modestly
reduced.
Next, we evaluated hepatic steatosis, using histological and biochemical assessments. Com-
pared with WT littermate controls, Tg/0 and Tg/Tg mice show a dramatic reduction in hepatic
(G) ER stress and (H) antioxidant gene expression in high-fat fed WT and Tg/Tg mouse liver, n = 9 or 10. (I) Mitochondrial superoxide production and (J)
mitochondrial membrane potential (ΔΨm) in HepG2 cells ectopically expressing LacZ (control) or LRPPRC n = 24. (K) Immunoblot and quantification of
phospho-AKT in cultured primary hepatocytes from chow-fedWT and Tg/Tg mice treated with 25nM insulin, n = 3. (L) Immunoblot and (M) quantification of
membrane or (N) membrane: cytosolic PKCε in high-fat fedWT and Tg/Tg mouse livers, n = 5 or 6. Data are mean ± SEM, *p<0.05, **p<0.01, ***p<0.001
vs. WT by two-way ANOVA (A, B), two-tailed unpaired Student’s t-test (insets, F, H, J, K), mixed model with Bonferroni correction (C) or one-tailed unpaired
Student’s t-test (M, N).
doi:10.1371/journal.pone.0125617.g003
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lipid content (Fig 4A and S4 Fig). We also graded hepatosteatosis, using a well characterized
grading system [25]. The frequency of mice with healthy livers was markedly increased in mice
with augmented hepatic OXPHOS (30% Tg/Tg vs 0% control), and there was 2.6-fold reduc-
tion in steatotic livers (30% Tg/Tg vs. 78% control, Fig 4D). Consistent with these results, bio-
chemical measurement of hepatic triglycerides and the expression of Fsp27, a gene that marks
lipid size, were both reduced in livers from Tg/Tg mice (Fig 4E and 4F). This reduced lipid bur-
den may explain diminished PKCε activation. Taken together, these data argue that augmenta-
tion of hepatic OXPHOS by ectopic expression of LRPPRC mitigates both steatosis and
inflammation in NAFLD.
Fig 4. Augmented hepatic OXPHOS interdicts NAFLD. (A) Representative histological sections of livers from wild-type littermate control mice (WT) and
LRPPRC double hemizygous (Tg/Tg) mice. (B) Pathologic classification of inflammation in livers of the samemice. (C) Expression of inflammatory genes in
livers of WT and Tg/Tg mice fed a high-fat diet for 12 weeks. (D) Pathologic classification of steatosis in high-fat fedWT and Tg/Tg mouse livers. (E)
Biochemical determination of triglyceride content in the same samples. (F) Determination of Fsp27 expression in high-fat fed WT and Tg/Tg livers. (G) Serum
triglyceride content in the samemice. Expression of genes involved in (H) lipid export, (I) lipid uptake, (J) Lipogenesis, and (K) fatty acid β-oxidation in high-
fat fedWT and Tg/Tg mouse livers. For all experiments, n = 9 or 10. Data are mean ± SEM *p<0.05, **p<0.01, ***p<0.001 vs. WT by chi-squared analysis
(B, D), 2-way ANOVA with Bonferroni’s post-test (C), or by two-tailed, unpaired Student’s t-test (D-K).
doi:10.1371/journal.pone.0125617.g004
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Regulation of hepatic lipid content is complex process that is dependent on integrated ac-
tion of lipid transport, lipogenesis, and fatty acid oxidation. For example, an increase in hepatic
lipid export can reduce hepatic steatosis but adversely increase serum triglycerides [34,35].
Similarly, a decrease in hepatic lipid uptake can reduce steatosis but adversely increase serum
triglyceride. In mice with augmented hepatic OXPHOS, fasting serum triglycerides were not al-
tered (Fig 4G), a finding which could imply that hepatic lipid export and import were not sig-
nificantly altered. Consistent with this, genes involved in lipid transport were unchanged in
Tg/Tg mice (Fig 4H and 4I).
Because hepatic lipogenesis is increased in patients with NAFLD [36], we quantified the ex-
pression of lipogenic genes. While Srebp1c was unchanged, FasnmRNA was modestly reduced
about 35% in Tg/Tg mice (Fig 4J). Even so, the difference in Fasn is unlikely to explain reduced
hepatic steatosis in LRPPRC transgenic mice, since ablation of Fasn in mice paradoxically in-
creases hepatic lipid content [37]. Additionally, we assessed the expression of ChREBP iso-
forms, a transcription factor which regulates Fasn and Acc. However, in Tg/Tg mice, total
ChREBP, ChREBP-a, and ChREBP-β exhibited only minor changes compared to wild-type
littermate controls.
We previously showed that ectopic Lrpprc expression promotes fatty acid β-oxidation in
primary hepatocytes [18]. In this model, LRPPRC enhanced fatty acid oxidation without affect-
ing the expression of genes involved in fatty acid β-oxidation. Consistent with our previous
study, the expression of genes involved in fatty acid β-oxidation gene were unchanged in livers
Tg/Tg mice (Fig 4K). These data imply metabolic control of fatty acid β-oxidation is critical.
Augmented OXPHOS increases hepatic NAD+, which governs complete
fatty acid oxidation
Status of hepatic OXPHOS directly correlates with fatty acid oxidation in liver. For example, in
patients suffering from Leigh syndrome, which impairs OXPHOS, there is increased hepatic
steatosis and reduced β-oxidative capacity [38,39]. Furthermore, pharmacological inhibition of
OXPHOS impairs mitochondrial oxidation of fatty acids [40]. We previously published that ec-
topically expressing Lrpprc in hepatocytes increased OXPHOS as well as palmitate oxidation
without alterations in the fatty acid oxidative program [18]. The absence of substantial genetic
changes in these models of OXPHOS as well as in Tg/Tg mice (Fig 4K) could suggest a meta-
bolic control of fatty acid oxidation. We, therefore, sought to investigate if metabolic control
via augmented OXPHOS could promote complete fatty acid oxidation.
Complete oxidation of lipids requires oxidation of acetyl-CoA by the citric acid cycle, a pro-
cess dependent on the oxidized electron carrier NAD+ (Fig 5A). Conversely, NADH opposes
citric acid (TCA) cycle oxidation. The electron transport chain plays a central role in coenzyme
concentration as it converts NADH to NAD+. Thus, we hypothesized that augmented
OXPHOS might increase NAD+, which in turn might promote complete oxidation via the cit-
ric acid cycle. We measured NAD+ levels in mice with augmented OXPHOS fed a chow diet.
As shown in Fig 5B and 5C, both Tg/0 and Tg/Tg mice had increased levels of NAD+ and the
ratio of oxidized to reduced carriers ([NAD+]/[NADH]). We did not, however, observe any al-
teration in the rate limiting enzymes involved in NAD+ synthesis (Fig 5D).
Next, we confirmed these findings in a cellular model of hepatic OXPHOS. To exclude
pleiotropic effects of LRPPRC expression, we measured the effects of chemical activators and
inhibitors of cellular respiration on the ratio of [NAD+]/[NADH] in cultured primary mouse
hepatocytes. To first test the effects of metabolic excess on [NAD+]/[NADH], we treated hepa-
tocytes with palmitic acid. Consistent with previous work in hepatoma cell lines [41], palmitate
enhanced [NAD+]/[NADH] in primary hepatocytes containing normal respiratory capacity
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Fig 5. OXPHOS dictates NAD+, promoting complete oxidation of fatty acids (A) Fatty acid metabolic pathway in liver: NAD+ dependent β-oxidation
catalyzes lipids to acetyl-CoA and ketone bodies (incomplete oxidation). Acetyl-CoA is further metabolized via the NAD+ dependent TCA cycle, yielding
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(Fig 5E). We then wished to understand if modulation of cellular respiration altered [NAD+]/
[NADH]. Inhibition of electron transport using the Complex I inhibitor rotenone significantly
diminished [NAD+]/[NADH]. In contrast, increasing cellular respiration by the uncoupling
agent FCCP enhanced [NAD+]/[NADH] levels. Since OXPHOS is disrupted in patients with
NAFLD, we interrogated the consequences of nutrient excess in the context of a dysfunctional
respiratory chain by measuring the availability of NAD+ in hepatocytes concurrently treated
with palmitic acid and rotenone. As shown in Fig 5E, the addition of fatty acids synergistically
diminished [NAD+]/[NADH] in hepatocytes treated with rotenone. This suggests that
[NAD+]/[NADH] levels may only be disrupted by nutrient flux in the presence of impaired
OXPHOS.
Given the availability of NAD+ is dictated by OXPHOS, and augmentated OXPHOS drives
fatty acid oxidation, we evaluated whether increased NAD+ could was the basis for complete
oxidation of fatty acids. To test this, we treated primary mouse hepatocytes with the NAD+
precursor nicotinamide (NAM). Treatment with NAM directly correlated with cellular NAD+
levels in cultured primary hepatocytes (Fig 5F). We next investigated if increased NAD+ pro-
moted complete oxidation of fatty acids by measuring the complete oxidation of palmitate to
CO2 in the presence of increasing NAM, which increases NAD
+ levels. As shown in Fig 5G,
NAM promoted a dose-dependent increase in complete palmitate oxidation to CO2, suggesting
that NAD+ is capable of driving fatty acid oxidation. Importantly, we did not observe any ef-
fects of NAM on mitochondrial content as measured by the mitochondrial protein citrate
synthase (Fig 5H).
Previous work indicates that NAD + activates the mitochondrial protein SIRT3, which dea-
cetylates certain proteins involved in fatty acid β-oxidation and augments fatty acid oxidation
[42]. We, therefore, assessed if the effects of NAM on palmitate oxidation were entirely depen-
dent on SIRT3. Consistent with previously published data, primary hepatocytes lacking Sirt3
(Sirt3 KO) had reduced fatty acid oxidative capacity when compared with wild-type hepato-
cytes (Fig 5I). Using NAM to increase NAD+, however, the deficit in Sirt3 KO hepatocytes was
rescued. These data imply the effects of NAD+ on increasing complete fatty acid oxidation are
independent of SIRT3 mediated deacetylation.
We next sought to query the effects of exogenous NAD+ in hepatocytes with inhibited
OXPHOS. To do so, we treated primary hepatocytes with rotenone, and measured complete
oxidation of palmitate to carbon dioxide. Rotenone reduced palmitate oxidation by 20% com-
pared with vehicle treated hepatocytes (Fig 5J). In the presence of NAM, however, complete
fatty acid oxidation was rescued in OXPHOS deficient hepatocytes. Finally, we evaluated if
NAD+ was capable of enhancing palmitate oxidation in the setting of augmented cellular respi-
ration. We treated primary hepatocytes with the chemical uncoupler FCCP, which induces
maximal respiration via uncoupling electron transport from ATP synthesis. FCCP driven max-
imal respiration promoted palmitate oxidation and increased CO2 production two-fold (Fig
5K). This increase was potentiated in cells treated with NAM, indicating that NAD+ augment-
ed complete oxidation, even in the setting of increased cellular respiration. Taken together,
CO2 (complete oxidation). NAD
+ allosterically activates TCA cycling, while NADH inhibits this process. (B) NAD+ and (C) [NAD+]/[NADH] levels in chow fed
wild-type littermate control mice (WT), LRPPRC single hemizygous (Tg/0), and double hemizygous (Tg/Tg) mice.(D) NAD+ synthetic gene expression in WT
and Tg/Tg mice. (E) [NAD+]/[NADH] levels in cultured primary hepatocytes treated with 250 μM palmitic acid, 1 μM rotenone, or 4 μMFCCP. (F) NAD+ levels
in nicotinamide (NAM) treated cultured primary hepatocytes. (G) Palmitate oxidation to CO2 in cultured primary hepatocytes treated with NAM. (H)
Immunoblot of citrate synthase (CS) expression in cultured primary hepatocytes treated with NAM. (I) Palmitate oxidation in Sirt3 -/- (Sirt3 KO) primary
hepatocytes treated with NAM. Palmitate oxidation in primary hepatocytes treated with (J) rotenone or (K) FCCP and NAM. For all experiments, n = 3 or 4
Data are mean ± SEM *p<0.05, **p<0.01, ***p<0.001 vs. vehicle unless otherwise indicated and ###p<0.001 by two-tailed unpaired Student’s t-test (B, C,
E, G, I, J, K) or linear regression (F).
doi:10.1371/journal.pone.0125617.g005
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these data are consistent with a model of OXPHOS driven NAD+, which promotes complete
oxidation of lipids, which may explain reduced lipid accumulation in hepatocytes (Fig 6).
Discussion
In this report, we demonstrated that increased hepatic oxidative phosphorylation (OXPHOS)
increases NAD+, an allosteric activator of TCA cycle enzymes, which promotes complete oxi-
dation of fatty acids. Consistent with a favorable change in hepatic lipid homeostasis through
NAD+, mice with augmented hepatic OXPHOS had increased NAD+ and were protected from
NAFLD. Increasing NAD+ in mouse hepatocytes rescued incomplete fatty acid oxidation in
mice deficient for either OXPHOS or SIRT3 and synergistically increased complete oxidation
of fatty acids in hepatocytes with increased cellular respiration. As reported by others, mitiga-
tion of NAFLD was associated with improved whole-body insulin sensitivity, presumably due
to reduced liver inflammation and release of detrimental inflammatory cytokines. Overall,
these data identify a critical role for OXPHOS-mediated control of NAD+ in NAFLD (Fig 6).
Several studies have demonstrated that the ratio of [NADH]/[NAD+] is increased in
NAFLD [14,15]. Interestingly, in our studies, simply fluxing hepatocytes with palmitate did not
did not increase the [NADH]/[NAD+] ratio. In the presence of impaired OXPHOS, however,
the ratio was synergistically increased. This is important, since the ratio of [NADH]/[NAD+]
directly correlates with mitochondrial reactive oxygen species (ROS), an important determi-
nant of hepatic insulin resistance. These data may imply that nutrient excess coupled with
OXPHOS defects determine the severity of NAFLD.
The mechanism by which enhanced OXPHOS increases the [NAD+]/[NADH] is yet un-
clear. It is plausible that enhanced cycling of NADH through complex I of the electron trans-
port chain yields an increase in oxidized carrier intermediates. Loss of complex I in some
studies [43], as well as our data from rotenone inhibition, substantiate that complex I function
is critical for maintaining [NAD+]/[NADH]. Interestingly, mice with enhanced hepatic
OXPHOS also have increased total NAD+ pools, possibly suggesting an alteration in NAD
+ metabolism. Illustrating the complexity of this regulation, Karamanlidis et al., 2013 recently
Fig 6. Activation of hepatic OXPHOS increases cellular NAD+ and complete fatty acid oxidation, mitigating NAFLD. In obesity and nutrient excess,
increased ratio of reduced NADH to oxidized NAD+ inhibits complete oxidation of fatty acids in the liver, leading to lipid accumulation, PKCε activation, and
insulin resistance. Augmented hepatic OXPHOS, through enhanced redox cycling and/or increased ATP dependent NAD+ synthesis, increases the ratio of
[NAD+]/[NADH], thereby driving complete oxidation of fatty acids, reducing steatosis, and promoting insulin sensitivity. Additionally, enhanced OXPHOS
reduces reactive oxygen species, which may contribute to increased insulin sensitivity (not shown).
doi:10.1371/journal.pone.0125617.g006
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reported that complex I deficiency reduced the [NAD+]/[NADH] ratio but also perturbed the
pool size. These observations suggest that the regulation of NAD+ and NADH is complex, pre-
sumably because it is governed by many variables. In our study, we did not observe any alter-
ation in the rate limiting NAD+ synthetic genes. Ectopic expression of LRPPRC increases
intracellular ATP, a co-factor critical for NAD+ synthesis. It is, thus, conceivable that enhanced
OXPHOS increases cellular ATP, which in may in turn promote NAD+ synthesis. Coupled
with enhanced cycling at complex I, this could explain the increase in both total pool size and
[NAD+]/[NADH] ratio.
In our model which is protected against NAFLD and insulin resistance, respiration is cou-
pled, indicative bona fide OXPHOS. Shulman and colleagues, however, showed that uncoupl-
ing cellular respiration in mice was associated with improved insulin sensitivity [44,45].
Our work illustrates that augmenting cellular respiration, whether coupled (that is, bona fide
OXPHOS) or uncoupled, increases the ratio of [NAD+]/[NADH], implying a common mecha-
nism whereby respiration-mediated control of NAD+, which governs complete oxidation of
fatty acids and interdicts hepatic steatosis. This is important, because prior studies indicate that
treatment with NAD+ precursors niacin or nicotinamide mononucleotide may have beneficial
effects on fatty liver [46,47]. These effects are thought to be, in part, dependent on activation of
the sirtuin family of deacetylases. Here we have demonstrated that cellular NAD+ is capable of
promoting fatty acid oxidation in the absence of the mitochondrial sirtuin SIRT3. Moreover,
we did not observe any effects on mitochondrial biogenesis, a downstream effect of nuclear sir-
tuin SIRT1 activation. NAD+, is a potent activator of TCA cycle enzymes, whereas NADH is
an inhibitor. It is conceivable that increasing the ratio of [NAD+]/[NADH] or possibly increas-
ing the absolute concentration of NAD+, might stimulate TCA enzymes and promote complete
oxidation of fatty acids, independent of the activation of sirtuin proteins. Supporting a central
role for NAD+ levels, increasing NAD+ in OXPHOS deficient hepatocytes rescued complete
fatty acid oxidation in Sirt3 knockout primary hepatocytes. Despite these observations, we can-
not exclude other potentially salutary effects of increasing NAD+ that could enhance fatty acid
oxidation in hepatocytes.
Other studies have manipulated mitochondrial content in the context of NAFLD, however,
these manipulations have pleiotropic effects that confound interpretation. For example, ectopic
expression of the transcriptional co-activator PGC-1β in mouse liver improved hepatic steato-
sis [34,35], but also induced enzymes involved in lipid export. Hence, it is unclear how signifi-
cant OXPHOS per se was in this experimental model. More importantly, increased hepatic
lipid secretion in this model might adversely affect cardiovascular health, an adverse change in
serum lipids we did not observe in our mouse model which specifically augments OXPHOS.
Other studies have evaluated the role of OXPHOS in fatty liver by ablating OXPHOS in mouse
liver [48]. Ablation of OXPHOS in liver, however, is almost universally associated with reduced
fat mass. Adiposity is a potent regulator of whole-body insulin sensitivity. It is, thus, possible
that marked reductions in fat mass in models of impaired hepatic OXPHOS may offset adverse
changes in liver. In our model of augmented OXPHOS, we saw a modest decline in weight.
Even so, we suspect weight changes were not a major factor in our findings, as single and dou-
ble transgenic mice had nearly identical weights, however, mitigation of NAFLD and insulin
resistance was greatest only in double transgenic mice. Moreover, changes trending toward in-
sulin sensitivity preceded changes in weight.
In summary, activation of hepatic OXPHOS increases NAD+ and interdicts NAFLD. The
ratio of [NAD+]/[NADH] is dictated by cellular respiration and increases in NAD+ promote
complete oxidation of fatty acids. These changes are ultimately associated with reduced
cellular ROS, less activation of PKCε, and reduced inflammation, changes we believe promote
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whole-body and hepatic insulin sensitivity. OXPHOS-mediated control of NAD+ may prove a
safe and effective means to interdict NAFLD.
Supporting Information
S1 Fig. Hemizygous expression of LRPPRC promotes mitochondrial transcription. (A)
Lrpprc, mitochondrial polymerase (Polrmt), mitochondrial transcription factor A (Tfam), and
mitochondrial transcription factor B2 (Tfb2m) and (B) mitochondrially encoded respiratory
complex subunit gene expression in hemizygous liver specific LRPPRC transgenic (Tg/0) and
control livers. Data are mean ± SEM. p<0.05 by Student’s unpaired two-tailed t-test (A) or
2-way ANOVA (B).
(PDF)
S2 Fig. LRPPRC increases respiratory complex activity. Individual electron transport chain
complex activity of NADH-ubiquinone oxidoreductase (CI), ubiquinol-cytochrome c reduc-
tase (CIII), cytochrome c oxidase (CIV), and ATPase (CV) in control (LacZ) vs. LRPPRC re-
plete samples, normalized to citrate synthase activity (CS). Citrate synthase activity was
unchanged between groups. Data are mean ± SEM. p<0.05 by two-way ANOVA.
(PDF)
S3 Fig. Effects of LRPPRC on OXPHOS are maintained after high-fat feeding. (A) Relative
Lrpprc and (B) mitochondrially encoded respiratory subunit gene expression in livers of wild-
type (WT) and double-hemizygous liver-specific Lrpprc transgenic mice fed a high-fat diet. (C)
Protein expression in the same samples. Data are mean ± SEM. p<0.05 by Student’s unpaired
two-tailed t-test (A) or 2-way ANOVA (B).
(PDF)
S4 Fig. Hemizygous expression of LRPPRC demonstrates moderate protection from
NAFLD. (A) Representative H+E and (B) pathologic grading of wild-type (WT) and hemizy-
gous liver-specific LRPPRC transgenic mice (Tg/0) fed a high-fat diet for 12 weeks, n = 8–10
for WT and n = 6 for Tg/0. Data are mean ± SEM. p<0.05 by chi-square analysis.
(PDF)
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